Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BN 82451

Drug Profile

BN 82451

Alternative Names: BN-82451B; BN82451

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsen
  • Class Amines; Neuroprotectants; Phenols; Small molecules; Thiazoles
  • Mechanism of Action Lipid peroxidation inhibitors; Monoamine oxidase B inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Discontinued Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 31 May 2016 Ipsen completes enrolment in its phase II trial for Huntington's disease in Germany (NCT02231580)
  • 01 Sep 2014 Phase-II clinical trials in Huntington's disease in Germany (PO)
  • 26 Nov 2013 Phase-II clinical trials in Huntington's disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top